Sale of Shares and Director/PDMR Shareholding

Diaceutics PLC

("Diaceutics" or the "Company")

Sale of Shares and Director/PDMR Shareholding

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces that on 4 May 2021, Philip White, the Chief Financial Officer of Diaceutics, sold 200,000 ordinary shares of £0.002 each in the Company ("Ordinary Shares") at a price of 123 pence per Ordinary Share. The shares were sold for the purposes of settling a personal tax liability. As a result of the sale, Philip's shareholding is 1,756,389 Ordinary Shares, representing 2.09% of the Company's issued share capital.

Enquiries:

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - our Proprietary Diagnostic Network solution for the development and commercialisation of precision medicine diagnostics. The Company, listed on the AIM Market of the London Stock Exchange, has created commercially useful data sets for every precision medicine that has come to market. We have built the world's largest repository of diagnostic testing data with a growing network of 2,500 laboratories in 51 countries. www.diaceutics.com

About DXRX - The Diagnostic Network®

DXRX is Diaceutics' proprietary diagnostic network for precision medicine. DXRX is an end-to-end solution for the development and commercialisation of Precision Medicine diagnostics. The platform enables a vibrant marketplace where all stakeholders in Precision Medicine come to find trusted partners and collaborations in a secure, standardised way. DXRX provides access to a pipeline of global diagnostic testing data on one secure platform.